| 101783-9 |
Fusarium oxysporum DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Fusarium oxysporum DNA [Presence] in Specimen by NAA with probe detection |
|
MAJ |
DefinitionDescription |
|
|
pos/neg |
|
|
|
|
|
|
MICRO |
|
101783-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
F oxysporum DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; F oxysporum; F vaxinfectum; F. oxysporum DNA; Fusarium vasinfectum; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m49; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101784-7 |
Scopulariopsis brevicaulis DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Scopulariopsis brevicaulis DNA [Presence] in Specimen by NAA with probe detection |
|
NAM |
DefinitionDescription |
|
|
pos/neg |
|
|
|
|
|
|
MICRO |
|
101784-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
S. brevicaulis DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; S. brevicaulis; S. brevicaulis DNA; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101785-4 |
CYP2C Cluster Allele |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
CYP2C Cluster Allele [Genotype] in Blood or Tissue by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
101785-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CYP2C Clt Ale Geno Bld/T |
|
|
|
N |
|
Blood; CYP2C Clt Ale; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101786-2 |
Toxoplasma gondii DNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Toxoplasma gondii DNA [Presence] in Serum by RT-PCR |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101786-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
T gondii DNA Ser Ql |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Serum; SR; Strand Displacement Amplification; T gondii; T gondii DNA; TMA; Toxo; Toxoplasmosis; Transcription mediated amplification |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101787-0 |
B-cell lymphoma chromosome analysis |
Find |
Tiss |
Pt |
Doc |
FISH |
|
ACTIVE |
B-cell lymphoma chromosome analysis in Tissue by FISH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
101787-0 |
|
FISH |
|
|
Both |
|
|
|
0 |
B-cell lymphoma chromosome al Tiss FISH |
|
|
|
N |
|
B Cell; B-ALL; B-cell acute lymphoblastic leukemia; BCELLS; BLYM; Chrom analy; Chromosom; Chromosomes; Cytogenetics; Document; Finding; Findings; Fluorescent in situ hybridization; Karyotype; Molecular pathology; MOLPATH; Point in time; Random; Tissue; Tissue, unspecified |
2.76 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101788-8 |
Chronic lymphocytic leukemia gene rearrangements |
Find |
Bld/Bone mar |
Pt |
Doc |
FISH |
|
ACTIVE |
Chronic lymphocytic leukemia gene rearrangements in Blood or Marrow by FISH |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.REARRANGE |
|
101788-8 |
|
FISH |
|
|
Both |
|
|
|
0 |
CLL gene rearrange Bld/Mar FISH |
|
|
|
N |
|
B-cell CLL; Bld/Mar; Blood; BM; BON; Bone marrow; CLL; CLL gene; CLL gene rearrange; Document; Finding; Findings; Fluorescent in situ hybridization; Lymphoma 1; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Molecular pathology; MOLPATH; MOLPATH.REARRANGEMENTS; Point in time; Random; Rearr; Rearrangement; WB; Whole blood; Whole blood or Bone marrow |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101789-6 |
Malnutrition risk screening panel |
- |
^Patient |
Pt |
- |
Nutrition and dietetics |
|
ACTIVE |
Malnutrition risk screening |
|
MIN |
DefinitionDescription |
|
|
|
|
�© Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition and Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults. J Acad Nutr Diet. Apr 2020;120(4):709-713. doi:10.1016/j.jand.2019.09.011 Used with Permission |
|
|
|
|
PANEL.NUTRITION&DIET |
|
101789-6 |
|
Nutrition and dietetics |
|
|
Order |
|
|
|
0 |
Malnut scn risk |
|
|
|
N |
|
Asympt; Asymptomatic; Nutr+diet; Nutrition+Dietetics; Nutrsksc; Nutrsksc pnl; Pan; Panl; Pnl; Point in time; Random; Scn; SDOH |
2.79 |
2.75 |
|
Panel |
|
|
�© Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition and Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults. J Acad Nutr Diet. Apr 2020;120(4):709-713. doi:10.1016/j.jand.2019.09.011 Used with Permission |
|
|
|
|
|
Release 2.79: FORMULA: Removed incorrect value from formula; |
0 |
| 10179-0 |
Symptoms & diseases |
Hx |
Throat+Neck |
Pt |
Nar |
|
|
ACTIVE |
History of Throat and Neck disorders Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10179-0 |
|
|
|
|
|
|
|
|
0 |
Hx of Throat+Neck disorders |
|
|
|
|
|
H+P; H+P.HX; History; Narrative; P prime; Point in time; Random; Report; Sx; Symp + dis |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component and changed Property from "Find" to "Hx" per 8/2015 Clinical LOINC Committee decision |
0 |
| 101790-4 |
Platelet function panel |
- |
Plas |
Pt |
- |
Coag |
|
ACTIVE |
Platelet function profile in plasma |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.COAG |
|
101790-4 |
|
Coag |
|
|
Order |
|
|
|
0 |
Platelet Fn Pnl in plas |
|
|
|
N |
|
Closure time; Closure Tme; Clot; Clottable; COAGULATION; Coagulation assay; FCN; Func; Funct; Pan; PANEL.COAGULATION; Panl; Pl; Plasma; Platelet Fn Pnl; Platelets; Platelt; Plsm; Plt; Pnl; Point in time; Random; Thrombocyte; Thrombocytes; Tilt tube |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101791-2 |
Clostridium tetani toxoid and corynebacterium diphtheriae Ab panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Corynebacterium diphtheriae and Clostridium tetani toxoid Ab Panel - Serum or Plasma |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101791-2 |
|
|
|
|
Order |
|
|
|
0 |
DTABS panel |
|
|
|
N |
|
C diphtheriae; C tetani; C tetani Toxoid; c208; Diphtheria; Diptheria; DTABS panel; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; Rc208; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tet; Tetanus; Tetanus toxoid; Ttx |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101792-0 |
Scanned laboratory result |
Find |
{Setting} |
Pt |
Doc |
|
|
ACTIVE |
Scanned laboratory result |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
101792-0 |
|
|
|
|
|
|
|
|
0 |
Scanned lab result |
|
|
|
N |
|
DOC.ONT; Document; Finding; Findings; Point in time; Random; Scanned lab result |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: corrected capitalization; |
0 |
| 101793-8 |
Tianeptine |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Tianeptine [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101793-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Tianeptine Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Coaxil; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Stablon; Tatinol; Tianeptin; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 101794-6 |
Tianeptine |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Tianeptine [Presence] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101794-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Tianeptine Ur Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Coaxil; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stablon; Tatinol; Tianeptin; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101795-3 |
Tianeptine/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Tianeptine/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101795-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Tianeptine/Creat Ur Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Coaxil; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Stablon; Tatinol; Tianeptin; Tianeptine /Cr; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 101796-1 |
Psilocin/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Psilocin/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101796-1 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Psilocin/Creat Ur Cfm |
|
|
|
N |
|
4-hydroxy-dimethyltryptamine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 101797-9 |
8-aminoclonazolam |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
8-Aminoclonazolam [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101797-9 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
8-Aminoclonazolam Ur Ql Cfm |
|
|
|
N |
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101798-7 |
8-aminoclonazolam/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
8-Aminoclonazolam/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101798-7 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
8-Aminoclonazolam/Creat Ur Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 101799-5 |
2-Oxo-3-Hydroxy-Lysergate diethylamide/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
2-Oxo-3-Hydroxy-Lysergate diethylamide/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101799-5 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
2-oxo-3-OH-LDS/Creat Ur Cfm |
|
|
|
N |
|
2-oxo-3-OH-LDS; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; Hydrox; II; III; LC/MS/MS; LSD; LSD metabolite; Lysergic acid; Lysergic acid diethylamide; Mass concentration ratio; Mass ratio; MCRto; OH; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 1018-1 |
E Ab |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
E Ab [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
1018-1 |
|
|
|
|
Observation |
|
|
|
0 |
E Ab SerPl Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; BLOOD BANK; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Rh Blood Group System; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 10180-8 |
Symptoms & diseases |
Hx |
Throat+Neck |
Pt |
Nom |
|
|
ACTIVE |
History of Throat and Neck disorders |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10180-8 |
|
|
|
|
|
|
|
|
0 |
Hx of Throat+Neck disorders |
|
|
|
|
|
H+P; H+P.HX; History; Nominal; P prime; Point in time; Random; Sx; Symp + dis |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component and changed Property from "Find" to "Hx" per 8/2015 Clinical LOINC Committee decision |
0 |
| 101800-1 |
Lysergate diethylamide/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Lysergate diethylamide/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101800-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
LSD/Creat Ur Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; LSD; Lysergic acid; Lysergic acid diethylamide; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 101801-9 |
2-Oxo-3-Hydroxy-Lysergate diethylamide |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
2-Oxo-3-Hydroxy-Lysergate diethylamide [Presence] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101801-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2-oxo-3-OH-LDS Ur Ql Cfm |
|
|
|
N |
|
2-oxo-3-OH-LDS; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydrox; II; III; LC/MS/MS; LSD; LSD metabolite; Lysergic acid; Lysergic acid diethylamide; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101802-7 |
Brucella sp Ab.IgA |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Brucella sp IgA Ab [Presence] in Serum |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101802-7 |
|
|
|
|
Both |
|
|
|
0 |
Brucella IgA Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Bruc; Brucellosis; Immune globulin A; Immunoglobulin A; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; species; spp; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
Release 2.77: ANSWER_LIST_TYPE: Added example answer lists for 6625; |
0 |
| 101803-5 |
Malabsorption Evaluation Panel |
- |
Stool |
Pt |
- |
|
|
ACTIVE |
Malabsorption Evaluation Panel - Stool |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101803-5 |
|
|
|
|
Order |
|
|
|
0 |
Malabsorption Evaluation Panel Stl |
|
|
|
N |
|
Assessment; Bowel movement; Eval; Faecal; Faeces; Fecal; Feces; H&P; History and physical; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Stl; Stool = Fecal |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101804-3 |
DXA Calcaneus [T-score] Bone density |
Tscore |
Bone |
Pt |
Qn |
|
|
ACTIVE |
Bone DXA Calcaneus [T-score] Bone density |
|
MAJ |
DefinitionDescription |
|
|
Tscore |
|
|
|
|
|
|
RAD |
|
101804-3 |
|
|
|
|
Both |
|
|
|
0 |
DXA Bone Tscore |
|
|
|
N |
|
BMD; BON; Den; DXA Tscore; Imaging; Point in time; QNT; Quan; Quant; Quantitative; RADIOLOGY; Random; T prime; T-score |
2.76 |
2.75 |
|
|
|
|
|
|
|
{Tscore} |
|
|
|
0 |
